Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20


The liver-selective thyromimetic T-0681 influences reverse cholesterol transport and atherosclerosis development in mice.

Tancevski I, Demetz E, Eller P, Duwensee K, Hoefer J, Heim C, Stanzl U, Wehinger A, Auer K, Karer R, Huber J, Schgoer W, Van Eck M, Vanhoutte J, Fievet C, Stellaard F, Rudling M, Patsch JR, Ritsch A.

PLoS One. 2010 Jan 15;5(1):e8722. doi: 10.1371/journal.pone.0008722.


Influence of aspirin on SR-BI expression in human carotid plaques.

Wehinger A, Tancevski I, Seiler R, Frotschnig SM, Frantz S, Huber J, Eller P, Schgoer W, Foeger B, Patsch JR, Ritsch A.

Atherosclerosis. 2009 Sep;206(1):234-8. doi: 10.1016/j.atherosclerosis.2009.01.034. Epub 2009 Feb 3.


The thyromimetic T-0681 protects from atherosclerosis.

Tancevski I, Wehinger A, Demetz E, Hoefer J, Eller P, Huber E, Stanzl U, Duwensee K, Auer K, Schgoer W, Kuhn V, Fievet C, Stellaard F, Rudling M, Foeger B, Patsch JR, Ritsch A.

J Lipid Res. 2009 May;50(5):938-44. doi: 10.1194/jlr.M800553-JLR200. Epub 2008 Dec 22.


Reduced plasma high-density lipoprotein cholesterol in hyperthyroid mice coincides with decreased hepatic adenosine 5'-triphosphate-binding cassette transporter 1 expression.

Tancevski I, Wehinger A, Demetz E, Eller P, Duwensee K, Huber J, Hochegger K, Schgoer W, Fievet C, Stellaard F, Rudling M, Patsch JR, Ritsch A.

Endocrinology. 2008 Jul;149(7):3708-12. doi: 10.1210/en.2007-1387. Epub 2008 Apr 3.


The MTP -493TT genotype is associated with peripheral arterial disease: results from the Linz Peripheral Arterial Disease (LIPAD) Study.

Schgoer W, Eller P, Mueller T, Tancevski I, Wehinger A, Ulmer H, Sandhofer A, Ritsch A, Haltmayer M, Patsch JR.

Clin Biochem. 2008 Jun;41(9):712-6. doi: 10.1016/j.clinbiochem.2008.02.007. Epub 2008 Feb 21.


Scavenger receptor class B type I polymorphisms and peripheral arterial disease.

Ritsch A, Sonderegger G, Sandhofer A, Stanzl U, Tancevski I, Eller P, Schgoer W, Wehinger A, Mueller T, Haltmayer M, Patsch JR.

Metabolism. 2007 Aug;56(8):1135-41. Erratum in: Metabolism. 2007 Nov;56(11):1599. Sonderegger, Gudron [corrected to Sonderegger, Gudrun]; Stanzl, Ursala [corrected to Stanzl, Ursula]; Patsch, Joseph R [corrected to Patsch, Josef R].


Low phospholipid transfer protein (PLTP) is a risk factor for peripheral atherosclerosis.

Schgoer W, Mueller T, Jauhiainen M, Wehinger A, Gander R, Tancevski I, Salzmann K, Eller P, Ritsch A, Haltmayer M, Ehnholm C, Patsch JR, Foeger B.

Atherosclerosis. 2008 Jan;196(1):219-26. Epub 2007 Jun 5.


Phospholipid transfer protein augments apoptosis in THP-1-derived macrophages induced by lipolyzed hypertriglyceridemic plasma.

Wehinger A, Tancevski I, Schgoer W, Eller P, Hochegger K, Morak M, Hermetter A, Ritsch A, Patsch JR, Foeger B.

Arterioscler Thromb Vasc Biol. 2007 Apr;27(4):908-15. Epub 2007 Feb 1.


Hepatic ENPP1 expression is induced in diabetic rabbits.

Eller P, Hochegger K, Wehinger A, Tancevski I, Schgoer W, Ritsch A, Patsch JR.

Mamm Genome. 2006 Aug;17(8):886-91. Epub 2006 Aug 4.


Aspirin regulates expression and function of scavenger receptor-BI in macrophages: studies in primary human macrophages and in mice.

Tancevski I, Wehinger A, Schgoer W, Eller P, Cuzzocrea S, Foeger B, Patsch JR, Ritsch A.

FASEB J. 2006 Jul;20(9):1328-35.


In vivo application of adenoviral vectors purified by a Taqman Real Time PCR-supported chromatographic protocol.

Tancevski I, Wehinger A, Patsch JR, Ritsch A.

Int J Biol Macromol. 2006 Aug 15;39(1-3):77-82. Epub 2006 Mar 10.


Hepatic lipase polymorphism and increased risk of peripheral arterial disease.

Eller P, Schgoer W, Mueller T, Tancevski I, Wehinger A, Ulmer H, Foeger B, Haltmayer M, Ritsch A, Patsch JR.

J Intern Med. 2005 Oct;258(4):344-8.


Increased plasma levels of LDL cholesterol in rabbits after adenoviral overexpression of human scavenger receptor class B type I.

Tancevski I, Frank S, Massoner P, Stanzl U, Schgoer W, Wehinger A, Fievet C, Eller P, Patsch JR, Ritsch A.

J Mol Med (Berl). 2005 Nov;83(11):927-32. Epub 2005 Aug 24.


Lipoprotein(a) and coronary thrombosis and restenosis after stent placement.

Wehinger A, Kastrati A, Elezi S, Baum H, Braun S, Neumann FJ, Schömig A.

J Am Coll Cardiol. 1999 Mar 15;33(4):1005-12.


Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement.

Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzky M, Dirschinger J, Neumann FJ, Schömig A.

J Am Coll Cardiol. 1998 Dec;32(7):1866-73.


Clinical and angiographic outcome after stent placement for chronic coronary occlusion.

Elezi S, Kastrati A, Wehinger A, Walter H, Schühlen H, Hadamitzky M, Dirschinger J, Neumann FJ, Schömig A.

Am J Cardiol. 1998 Sep 15;82(6):803-6, A9.


Intracoronary stenting and risk for major adverse cardiac events during the first month.

Schühlen H, Kastrati A, Dirschinger J, Hausleiter J, Elezi S, Wehinger A, Pache J, Hadamitzky M, Schömig A.

Circulation. 1998 Jul 14;98(2):104-11.


Predictive factors of restenosis after coronary stent placement.

Kastrati A, Schömig A, Elezi S, Schühlen H, Dirschinger J, Hadamitzky M, Wehinger A, Hausleiter J, Walter H, Neumann FJ.

J Am Coll Cardiol. 1997 Nov 15;30(6):1428-36.


Antiplatelet effect of ticlopidine after coronary stenting.

Neumann FJ, Gawaz M, Dickfeld T, Wehinger A, Walter H, Blasini R, Schomig A.

J Am Coll Cardiol. 1997 Jun;29(7):1515-9.


[Echocaridographic measurements of left ventricle, heart volume, and maximal oxygen uptake (author's transl)].

Simon G, Staiger J, Wehinger A, Kindermann W, Keul J.

Med Klin. 1978 Oct 20;73(42):1457-62. German.


Supplemental Content

Loading ...
Support Center